The Effect of Mankai on Glycemic Control Among Patients With T2D - Trial NCT06416475
Access comprehensive clinical trial information for NCT06416475 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ben-Gurion University of the Negev and is currently Recruitment Completed. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 104 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Ben-Gurion University of the Negev
Timeline & Enrollment
Phase 2
Apr 30, 2024
Aug 15, 2024
Primary Outcome
HbA1c,Fasting glycemic and insulin resistance profiling
Summary
The investigators aim to explore the effect of daily supplementation of Wolfia globosa Mankai
 on HbA1c and insulin resistance response among participants with type 2 diabetes (T2D). The
 investigators hypothesize that adding daily Mankai to T2D's healthy nutrition might lower
 HbA1c and promote glycemic control.
 
 Methods: A 3-month pilot RCT among 104 patients with T2D, with two intervention arms
 consuming comparable bottle volumes of either crude plant Mankai beverage (60ml Mankai) or
 water (60ml) 3 times/day postprandially over 3 months. Blood, urine, fecal, and clinical
 measures will be taken at 0 and 3 months. Overall appetite, food intake, symptoms, and
 medical treatment will be monitored.
 
 Importance: This study's results will shed light on the effects of regular Mankai consumption
 on HbA1c among patients with T2D, which may reveal a new nutritional source to improve
 glycemic control in T2D.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06416475
Non-Device Trial